Published in:
Open Access
01-12-2018 | Letter
Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
Authors:
Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, Claudio Gasperini, Enrico Montanari, Pierluigi Navarra, Francesco Patti, Maria Pia Sormani, Angelo Ghezzi
Published in:
Neurology and Therapy
|
Issue 2/2018
Login to get access
Excerpt
We read with interest the letter by Comi et al. [
1] in response to our review [
2]. In the still complex therapeutic landscape of multiple sclerosis (MS), more complexity was added by the controversy following the commercialization of Copemyl
®, at times perplexing neurologists in their clinical practice. We thank Comi et al. for having provided additional information on the intricate question of possible differences between glatiramer acetate (GA) and glatiramoids. Indeed some references were not included in our review, e.g., some abstracts and papers not available as the full text. …
